Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 6, 2024
Distillery Therapeutics

Decreasing hepatic oxalate levels for MASH

BioCentury | Jan 16, 2024
Distillery Therapeutics

Inhibiting MRE11 lactylation for cancer

BioCentury | Jun 12, 2023
Deals

Seeking high-value drugs, Novartis adds kidney franchise in $3.2B Chinook takeout

Biotech’s later-stage candidates give pharma two chances at a blockbuster, starting with IgA nephropathy indication amid rising competition
BioCentury | Apr 11, 2023
Finance

April 11 Quick Takes: VintaBio debuts with $64M to tackle viral vector bottleneck

Plus: Moderna forecasts up to $15B in 2027 sales of respiratory franchise and updates from HI-Bio, Chinook, Impact-Junshi and more
BioCentury | Nov 18, 2021
Deals

Eyeing RNAi platform more than pipeline, Novo buys Dicerna for $3.3B

Building on prior deal around hepatic platform, takeout gives Novo broader access to Dicerna’s technology
BioCentury | Sep 7, 2018
Financial News

RNAi company Dicerna raises $100M follow-on

BioCentury | Apr 20, 2018
Company News

Dicerna, Alnylam settle RNAi dispute

BioCentury | Jun 14, 2017
Distillery Therapeutics

Cancer

BioCentury | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Lactate dehydrogenase A (LDHA)

Items per page:
1 - 10 of 15